Intravenous Alfacalcidol Once Weekly Pulse Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients

REFERENCES

• Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59:1187–1201.
   PubMed Web of Science ®Google Scholar
• Drüeke TB. Parathyroid gland hyperplasia in uremia. Kidney Int. 2001;59:1182–1183.
   PubMed Web of Science ®Google Scholar
• Coburn JW, Llach F. Renal osteodystrophy. In: Narins RG, ed. Clinical Disorders of Fluid and Electrolyte Metabolism. 5th ed, New York, NY: McGraw Hill Book Co.; 1994:1299–1377.
   Google Scholar
• Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis. 1997;29:862–865.
   PubMed Web of Science ®Google Scholar
• Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: An uphill battle. Am J Nephrol. 2004;24:422–426.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Tokumoto M, Tsuruya K, . Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant. 2008;23:3662–3669.
   Google Scholar
• Fournier A, Morinière Ph, Oprisiu R, . 1-Alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration. Nephron. 1995;71:254–283.
   Google Scholar
• Brandi L, Daugaard H, Egsmose C, . Intermittent intravenous followed by intermittent oral 1 alpha (OH)D3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med. 1996;239:353–360.
   PubMedGoogle Scholar
• Brandi L, Daugaard H, Nielsen PK, . Long-term effects of intravenous 1 alpha (OH) D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron. 1996;74:89–103.
   PubMedGoogle Scholar
• Statopolsky EA, Burke SK, Dillon MA. Renagel a non absorbed calcium and aluminum free phosphorus binder lowers serum phosphorus and parathyroid hormone. The Renagel Study Group. Kidney Int. 1999;55:299–307.
   Google Scholar
• Fukagawa M, Kazarna H, Shigematsu T. Management of patients with advanced secondary hyperparathyroidism: The Japanese approach. Nephrol Dial Transplant. 2002;17:1553–1557.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Fukagawa M, Koshikawa S, Kurokawa K. Recent progress in management of secondary hyperparathyroidism of chronic renal failure. Curr Opin Nephrol Hypertens. 1993; 2:558–565.
   Google Scholar
• Gallieni M, Brancaccio D. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? I. Medical intervention is the primary option in the treatment of advanced hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant. 1994;9:1816–1819.
   Google Scholar
• Ritz E. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? II. Early parathyroidectomy should be considered as the first choice. Nephrol Dial Transplant. 1994;9:1819–1821.
   Google Scholar
• Pitts TO, Piraino BH, Mitro R. Hyperparathyroidism and 1,25 dihydroxyvitamin D in mild, moderate and severe renal failure. J Clin Endocrinol Metab. 1988;67:876–881.
   PubMed Web of Science ®Google Scholar
• Andress DL. Intravenous versus oral vitamin D therapy in dialysis patients: What is the question? Am J Kidney Dis. 2001;38:s41.
   Web of Science ®Google Scholar
• Gallieni M, Brancaccio D, Padovese P, . Low dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int. 1992;42:1191–1198.
   PubMedGoogle Scholar
• Morinier PH, El Esper N, Viron B, . Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1a-(OH)-D3, oral CaCO3 and low dialysate calcium. Kidney Int. 1993;43(Suppl. 41):121–124
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guide lines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S202.
   PubMedGoogle Scholar
• Cannata JB. Indications and limitations of intravenous calcitriol. Nefrologia. 1995;55:307–314.
   Google Scholar
• Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: A prevalence study. Surgery. 1997;122:1083–1090.
   PubMed Web of Science ®Google Scholar
• Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021.
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483.
   PubMed Web of Science ®Google Scholar
• London GM, Guerin AP, Marchais SL, . Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–1740.
   PubMed Web of Science ®Google Scholar
• Melamed ML, Eustace LA, Plantinga L, . Changes in serum calcium, phosphorus, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int. 2006;70:351–357.
   PubMed Web of Science ®Google Scholar
• González MT, Torregrosa JV, Colomé E, . Efficacy of Intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis. Nephron Clin Pract. 2008;108:c141–c147.
   Google Scholar
• Shoji T, Shinohara K, Kimoto E, . Lower risk for cardiovascular mortality in oral 1alpha-hydroxyvitamin D3 users in a hemodialysis population. Nephrol Dial Transplant. 2004; 19:179–184.
   PubMed Web of Science ®Google Scholar
• Tentori F, Hunt WC, Stidley CA, . Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865.
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA. Vitamin D analogs: Actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol. 2004;24:456–459.
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Ofsthun MN, . Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125.
   PubMed Web of Science ®Google Scholar
• Palmer SC, McGregor DO, Macaskill P, . Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147:840–853.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long term effects of sevelamer hydrochloride on the calcium  ×  phosphorus product and lipid profile of hemodialysis patients. Nephrol Dial Transplant. 1999;14:2907–2914.
   PubMed Web of Science ®Google Scholar
• Behets GL, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: A new phosphorus binder. Curr Opin Nephrol Hypertens. 2004;13:403–409.
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KL, de Francisco ALM, . Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525.
   PubMed Web of Science ®Google Scholar